Celia Hart, PhD, represents Supernova Invest and has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and is currently an Investment Director and Partner. Previously, Celia worked for Cambridge Antibody Technology, UK (now MedImmune) holding different positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in collaboration with international biotechnology and pharmaceutical partners. In France, she assessed new business opportunities for the European Synchrotron Radiation Facility (ESRF) and the Atomic Energy Commission (CEA). She serves (or has served) on the boards of Acusurgical, Algaia, Carthéra, Diabeloop, Fermentalg, Keranova, NH Theraguix and Theranexus. Celia holds a degree in chemistry from the University of Geneva in Switzerland, a PhD from Oxford University and an MBA from Grenoble École de Management in France.
